JP2014510518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510518A5 JP2014510518A5 JP2013553420A JP2013553420A JP2014510518A5 JP 2014510518 A5 JP2014510518 A5 JP 2014510518A5 JP 2013553420 A JP2013553420 A JP 2013553420A JP 2013553420 A JP2013553420 A JP 2013553420A JP 2014510518 A5 JP2014510518 A5 JP 2014510518A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hsa
- substitution
- amino acid
- fcrn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 229920001184 polypeptide Polymers 0.000 claims 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims 38
- 102000008100 Human Serum Albumin Human genes 0.000 claims 25
- 108091006905 Human Serum Albumin Proteins 0.000 claims 25
- 238000006467 substitution reaction Methods 0.000 claims 19
- 235000018102 proteins Nutrition 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 12
- 150000001413 amino acids Chemical group 0.000 claims 12
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 11
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 6
- 229960000310 isoleucine Drugs 0.000 claims 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000004471 Glycine Substances 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 235000018417 cysteine Nutrition 0.000 claims 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 230000005714 functional activity Effects 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2011/024855 | 2011-02-15 | ||
| PCT/US2011/024855 WO2011103076A1 (en) | 2010-02-16 | 2011-02-15 | Hsa-related compositions and methods of use |
| PCT/US2011/047040 WO2012112188A1 (en) | 2011-02-15 | 2011-08-09 | Hsa-related compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014510518A JP2014510518A (ja) | 2014-05-01 |
| JP2014510518A5 true JP2014510518A5 (OSRAM) | 2014-09-04 |
Family
ID=46675795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553420A Pending JP2014510518A (ja) | 2011-02-15 | 2011-08-09 | Ｈｓａ関連組成物および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2675471A4 (OSRAM) |
| JP (1) | JP2014510518A (OSRAM) |
| KR (1) | KR20140012094A (OSRAM) |
| CN (1) | CN103379915A (OSRAM) |
| AU (1) | AU2011359378A1 (OSRAM) |
| CA (1) | CA2826683A1 (OSRAM) |
| WO (1) | WO2012112188A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| JP2013509170A (ja) | 2009-10-30 | 2013-03-14 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | アルブミン変異体 |
| ES2678144T3 (es) * | 2010-02-16 | 2018-08-09 | Medimmune, Llc | Composiciones relacionadas con SAH y métodos de uso |
| WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| CN103649123B (zh) | 2011-06-13 | 2017-05-24 | Csl有限公司 | 抗g‑csfr抗体及其用途 |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013135896A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
| RU2670063C2 (ru) * | 2012-11-08 | 2018-10-17 | Альбумедикс А/С | Варианты альбумина |
| EP2956002B1 (en) | 2013-02-16 | 2017-09-06 | Albumedix A/S | Pharmacokinetic animal model |
| CN105209482B (zh) * | 2013-03-15 | 2022-04-29 | 阿菲博迪公司 | 新的多肽 |
| PL3007717T3 (pl) * | 2013-06-12 | 2018-12-31 | Pharis Biotec Gmbh | Peptydy o antagonistycznej aktywności w stosunku do naturalnego CXCR4 |
| WO2015036579A1 (en) * | 2013-09-13 | 2015-03-19 | Novozymes Biopharma Dk A/S | Albumin variants |
| CA2928700C (en) * | 2013-11-01 | 2019-01-15 | University Of Oslo | Albumin variants and uses thereof |
| KR20240093725A (ko) | 2015-03-12 | 2024-06-24 | 메디뮨 엘엘씨 | 알부민 융합 단백질의 정제 방법 |
| EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
| JP6893504B2 (ja) * | 2015-09-23 | 2021-06-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプｉｉｉドメイン |
| CA3005953A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix Ltd | Improved protein expression strains |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| CN110337590A (zh) | 2016-11-04 | 2019-10-15 | 奥胡斯大学 | 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗 |
| EP4026908A1 (en) | 2017-06-20 | 2022-07-13 | Albumedix Ltd | Improved protein expression strains |
| ES2939461T3 (es) | 2017-11-29 | 2023-04-24 | Csl Ltd | Método para tratar o prevenir la lesión por isquemia-reperfusión |
| US12281160B2 (en) | 2018-03-23 | 2025-04-22 | Csl Limited | Method of treating asthma |
| KR102854142B1 (ko) | 2018-05-16 | 2025-09-04 | 시에스엘 리미티드 | 가용성 보체 수용체 1형 변이체 및 이의 용도 |
| BR112021008105A2 (pt) | 2018-10-29 | 2021-08-03 | Biogen Ma Inc. | variantes de fc5 humanizadas e estabilizadas para intensificação de transporte através de barreira hematoencefálica |
| MX2022002638A (es) | 2019-09-06 | 2022-03-25 | Novartis Ag | Proteinas de fusion terapeuticas. |
| EP4069200A1 (en) | 2019-12-04 | 2022-10-12 | Albumedix Ltd | Methods and compositions produced thereby |
| CN114478800B (zh) * | 2021-02-05 | 2022-10-11 | 华南理工大学 | 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用 |
| CN113912730B (zh) * | 2021-12-14 | 2022-03-04 | 北京科诺信诚科技有限公司 | 缓释的抗FcRn抗体或抗原结合片段及其应用 |
| EP4608448A1 (en) | 2022-10-28 | 2025-09-03 | Aarhus Universitet | Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response |
| EP4442251A1 (en) | 2023-04-05 | 2024-10-09 | Albumedix Ltd | Formulations and uses thereof |
| WO2025007195A1 (en) | 2023-07-05 | 2025-01-09 | CSL Innovation Pty Ltd | Methods of treating or preventing a complication of sickle cell disease |
| WO2025158071A1 (en) | 2024-01-26 | 2025-07-31 | Sartorius Albumedix Limited | Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404270D0 (en) * | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| KR20110008086A (ko) * | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| CA2757897A1 (en) * | 2009-04-08 | 2010-10-14 | Anna M. Wu | Human protein scaffold with controlled serum pharmacokinetics |
| ES2678144T3 (es) * | 2010-02-16 | 2018-08-09 | Medimmune, Llc | Composiciones relacionadas con SAH y métodos de uso |
-
2011
- 2011-08-09 JP JP2013553420A patent/JP2014510518A/ja active Pending
- 2011-08-09 KR KR1020137024189A patent/KR20140012094A/ko not_active Withdrawn
- 2011-08-09 CA CA2826683A patent/CA2826683A1/en not_active Abandoned
- 2011-08-09 EP EP11858565.2A patent/EP2675471A4/en not_active Withdrawn
- 2011-08-09 CN CN2011800674634A patent/CN103379915A/zh active Pending
- 2011-08-09 WO PCT/US2011/047040 patent/WO2012112188A1/en not_active Ceased
- 2011-08-09 AU AU2011359378A patent/AU2011359378A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510518A5 (OSRAM) | ||
| JP2016052315A5 (OSRAM) | ||
| JP2013517783A5 (OSRAM) | ||
| JP2016512213A5 (OSRAM) | ||
| NZ610075A (en) | Cxcr2 binding polypeptides | |
| JP2018171063A5 (OSRAM) | ||
| JP2013545724A5 (OSRAM) | ||
| JP2015212284A5 (OSRAM) | ||
| CA2502904A1 (en) | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis | |
| JP2017512063A5 (OSRAM) | ||
| WO2015063611A4 (en) | Albumin variants and uses thereof | |
| JP2015504052A5 (OSRAM) | ||
| JP2018521640A5 (OSRAM) | ||
| JP2011501951A5 (OSRAM) | ||
| JP2005120106A5 (OSRAM) | ||
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| IL276286B2 (en) | FC variants with improved binding to FCRN and extended half-life | |
| EA036805B8 (ru) | Белок cd24 для подавления ответа хозяина на damp | |
| JP2015525217A5 (OSRAM) | ||
| JP2013534812A5 (OSRAM) | ||
| JP2013520426A5 (OSRAM) | ||
| JP2010068806A5 (OSRAM) | ||
| JP2002206000A5 (OSRAM) | ||
| JP2018538356A5 (OSRAM) | ||
| CN115443288A (zh) | 一种免疫球蛋白降解酶IdeE的突变体 |